BC Innovations | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

Non-invasive biomarkers in NASH are beginning to show where and how they can upstage liver biopsies, with the first impact appearing in patient recruitment. The biggest value will come when they can serve as regulatory...
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
BC Week In Review | Jan 5, 2018
Company News

Roche acquiring Ignyta for $1.7B

Roche (SIX:ROG; OTCQX:RHHBY) is acquiring cancer company Ignyta Inc. (NASDAQ:RXDX) for $27 per share, or $1.7 billion, in cash. The price is a 74% premium to Ignyta's close Thursday of $15.55. The deal gives Roche...
BC Extra | Dec 22, 2017
Company News

Roche acquiring Ignyta for $1.7B

Roche (SIX:ROG; OTCQX:RHHBY) is acquiring cancer company Ignyta Inc. (NASDAQ:RXDX) for $27 per share, or $1.7 billion, in cash. The price is a 74% premium to Ignyta's close Thursday of $15.55. The deal gives Roche...
BC Innovations | Aug 29, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggesting inhibiting LOXL2 could help treat metastatic breast cancer. In a mouse model of breast cancer, mammary gland-specific knockout of LOXL2 decreased lung metastatic burden and the number circulating tumor...
BC Innovations | Aug 17, 2017
Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BC Innovations | May 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies identified a LOX inhibitor that could help treat breast cancer. In in vitro LOX activity assays, a thiophenylmethanamine-based compound inhibited LOX with an IC 50 of 890 nM. In a...
BioCentury | Apr 14, 2017
Product Development

New endpoints in NASH

Data on mid-stage NASH candidates to be presented at the European Association for the Study of the Liver’s International Liver Congress this month won’t enable solid comparisons with each other or with more advanced programs....
BC Innovations | Jan 11, 2017
Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample and mouse studies suggest inhibiting LOXL2 could help treat heart failure. LOXL2 levels were higher in serum samples from heart failure patients and cardiac tissue samples from cardiomyopathy patients than...
BC Week In Review | Dec 9, 2016
Company News

PharmAkea, Celgene deal

PharmAkea and Celgene extended by nine months a deal to use PharmAkea's drug discovery platform to discover and develop small molecules to treat fibrotic diseases. Celgene committed $9 million to PharmAkea to extend the deal....
Items per page:
1 - 10 of 77